+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemoglobinopathy - Global Market Trajectory & Analytics

  • PDF Icon


  • 227 Pages
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309474
Global Hemoglobinopathy Market to Reach $823.4 Million by 2027

Amid the COVID-19 crisis, the global market for Hemoglobinopathy estimated at US$517.2 Million in the year 2020, is projected to reach a revised size of US$823.4 Million by 2027, growing at a CAGR of 6.9% over the analysis period 2020-2027. Sickle Cell Disease, one of the segments analyzed in the report, is projected to record a 6.5% CAGR and reach US$449.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Beta Thalassemia segment is readjusted to a revised 7.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $152.8 Million, While China is Forecast to Grow at 6.5% CAGR

The Hemoglobinopathy market in the U.S. is estimated at US$152.8 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$144.5 Million by the year 2027 trailing a CAGR of 6.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.5% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Alpha Thalassemia Segment to Record 7.9% CAGR

In the global Alpha Thalassemia segment, USA, Canada, Japan, China and Europe will drive the 8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$60 Million in the year 2020 will reach a projected size of US$102.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$95.2 Million by the year 2027.

Select Competitors (Total 38 Featured):
  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH
Frequently Asked Questions about the Global Market for Hemoglobinopathy

What is the estimated value of the Global Market for Hemoglobinopathy?

The Global Market for Hemoglobinopathy was estimated to be valued at $517.2 Million in 2020.

What is the growth rate of the Global Market for Hemoglobinopathy?

The growth rate of the Global Market for Hemoglobinopathy is 6.9%, with an estimated value of $823.4 Million by 2027.

What is the forecasted size of the Global Market for Hemoglobinopathy?

The Global Market for Hemoglobinopathy is estimated to be worth $823.4 Million by 2027.

Table of Contents


  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession


  • Total Companies Profiled: 38